|
|
|||||||||||
Maudsley Hospital, Denmark Hill, London SE5 8AZ
Novartis Pharmaceuticals UK, Frimley, Camberley, Surrey
Institute of Psychiatry, Denmark Hill, London
|
|
Abstract |
|---|
|
|
|---|
We aimed to find out how patients on clozapine felt about clozapine treatment. A structured questionnaire was given to 1284 consecutive patients attending 27 clozapine clinics in the UK.
RESULTS
The response rate was 44.4% (570 forms returned). This cohort of responders to the questionnaire consisted, for the most part, of Caucasian males who had been taking clozapine for more than 2 years. Respondents expressed largely favorable views on clozapine treatment. For example, 86.1% claimed to feel better on clozapine and 88.6% claimed to prefer to remain on clozapine than to change to another drug. Many patients stated that they disliked having to undergo blood testing, but a large majority (87.0%) felt that the advantages of clozapine outweighed disadvantages. All other responses supported this overall favourable view of clozapine therapy.
CLINICAL IMPLICATIONS
Patients stabilised on clozapine are largely content with their treatment. These results suggest that clozapine is effective as assessed by patients' own standards and that adherence to therapy is likely to be good.
DECLARATION OF INTEREST
L.S., L.G. and J.B. are employees of Novartis Pharmaceuticals UK.
|
|
Introduction |
|---|
|
|
|---|
The widespread use of clozapine is very probably inhibited by its acute adverse effect burden (Dev & Krupp, 1995) and by the need for close haematological monitoring. Nevertheless, acute adverse effects are usually manageable (Naber, 1999) and patient satisfaction with treatment, although not widely evaluated, appears to be high (Wolfson & Paton, 1996). It might be concluded, therefore, that clinician expectation or observation differed importantly from patient experience and perception.
We sought to evaluate patient perceptions of treatment in a large sample of subjects attending formal clozapine clinics in UK hospitals.
|
|
The study |
|---|
|
|
|---|
|
|
Findings |
|---|
|
|
|---|
Patient characteristics
Respondents were predominately men (63.3%) and Caucasian (89.5%), but
African-Caribbeans (4.9%) and Asians (2.8%) were also represented.
The age of patient respondents ranged from 18 to over 65 years with the majority aged between 25 and 44 (Table 1).
|
Most respondents had been taking clozapine for 2 years or more (see Table 2).
|
Previous therapy
Patients were asked to record the medication they were receiving
immediately before starting clozapine. Details are given in
Table 3.
|
Perceptions of clozapine treatment
Respondents were broadly favourable in their views of clozapine treatment.
When asked to compare clozapine with previous treatment, the overwhelming
majority of respondents rated clozapine as being better (62.1% much
better, 24.0% slightly better). Relatively few rated
clozapine about the same (9.8%) and a small minority felt
clozapine to be slightly worse (1.8%) or much
worse (0.9%) (n=570; 1.4% gave no reply). An open question on
the perceived benefits of clozapine treatment revealed that efficacy benefits
were most apparent: 35.4% (202 of 570 respondents) cited feeling
better as something they liked about clozapine. Relatively few (8.4%)
cited improvements in tolerability. A similar open question asked patients
what it was they did not like about clozapine. Blood tests were most often
cited in this regard (24.2%), followed by drowsiness (13.0%) and increased
salivation (9.8%). Weight gain was mentioned by only 5.4% of respondents
(n=570; 19% gave no reply). A further question evaluated preference
for treatment. Overall, 88.6% of respondents claimed that they would prefer to
stay on clozapine, with 6.5% preferring previous treatment (n=570;
4.9% did not give a preference). A similar proportion (87.0%) felt that the
advantages of clozapine outweighed disadvantages (n=570; 6.5% did not
feel advantages outweighed disadvantages, 6.5% gave no reply).
These positive views were reflected in replies to question 14, which asked how patients lives had changed since starting clozapine. Overall, 57% reported finding it easier to mix with people, 42.9% said they now liked socialising, 52.9% had left hospital, 42.9% could now live in a hostel and 7.0% had obtained employment. Only 11.1% reported that their lives had not changed (n=570, 3% gave no reply).
Blood testing
Patients were asked whether or not they knew the reasons for blood testing
with clozapine. Most (80.5%) claimed to know the reason for blood testing
(17.4% claimed they did not know, 2.1% did not reply (n=570)). Among
those claiming to know the reason for blood testing (n=459) 58.6%
cited the need to check white cell count as the reason, with a further 10.5%
mentioning the need to protect against infection and 2.4% directly citing the
danger of neutropenia. Overall, 6.1% did not give a reason and
12.4% gave the wrong reason. Information on blood testing had been provided by
doctors (60.8%, n=459), nursing staff (56.9%), a relative (4.6%) and
by a pharmacist (3.7%). Some 85% felt they had been given enough information
about clozapine.
When asked for views on regular blood tests, 64% (n=570) claimed to feel that "they're OK - a necessary part of treatment" and a further 4.7% claimed to look forward to blood tests. On the negative side, 28.2% claimed that they did not like blood tests much or at all and a further 1.6% said that blood tests made them want to stop taking clozapine.
|
|
Comments |
|---|
|
|
|---|
In the main, respondents were positive in their perceptions of clozapine treatment. Overall, 86.1% of patients claimed to feel better on clozapine than on previous treatments, and a substantial majority felt that the drug's advantages outweighed its disadvantages. Not surprisingly, a similar large majority claimed they would prefer to stay on clozapine rather than go back to previous treatment.
It was also encouraging to discover that most respondents knew the reasons for blood testing with clozapine and that a majority felt indifferent or positive about the necessity for them. However, an important minority of patients claimed not to like blood tests, with a small number stating that blood tests made them want to stop clozapine. Moreover, blood tests were most often given as the aspect of clozapine treatment that respondents did not like.
The large number of respondents in this survey makes more likely the probability that our results are broadly representative of clozapine patients in general. However, our response rate (44.4%) obviously represents a minority of patients surveyed, and our respondents formed something of a select group. All, by definition, were good attenders at clozapine clinics and all felt capable of or motivated to completing the questionnaire. Most were men and Caucasian and by far the majority had been on clozapine for longer than a year. It might be assumed, therefore, that our respondents are representative only of a sub-group of patients who have done well on clozapine and who undergo blood tests only monthly. (Although, an analysis of 77 patients on clozapine for less than 6 months revealed broadly similar attitudes to treatment.) It should also be noted that our questionnaire is not yet validated as a precise tool for evaluating patient perceptions.
In conclusion, in our somewhat select cohort of clozapine patients, clozapine was widely felt by respondents to be more effective than previous treatments. The need for blood tests was viewed negatively by some but, overall, patients expressed a clear preference for clozapine over former therapies. Future research should address perceptions of patients less well established on clozapine undergoing more frequent blood testing.
|
|
References |
|---|
|
|
|---|
FLEISCHHACKER, W.W. (1999) Clozapine: a comparison with other novel antipsychotics. Journal of Clinical Psychiatry, 60 (Suppl. 1), 30-34.
KANE, J., HONIGFIELD, G., SINGER, J., et al (1988) Clozaril collaborative study. Archives of General Psychiatry, 45, 789-796.[Abstract]
NABER, D. (1999) Optimizing clozapine treatment. Journal of Clinical Psychiatry, 60, 35-38.
TAYLOR, D. (1999) Treatment of refractory schizophrenia. Pharmaceutical Journal, (suppl. 1), 2-4.
WAHLBECK, K., CHEINE, M., ESSALI, A., et al
(1999) Evidence of clozapine's effectiveness in schizophrenia: a
systematic review and meta-analysis of randomized trials. American
Journal of Psychiatry, 156,
990-999.
WOLFSON, P. M. & PATON, C. (1996) Clozapine audit: what to do patients and relatives think? Journal of Mental Health, 5, 267-273.
This article has been cited by other articles:
![]() |
E. WHISKEY, T. WYKES, D. DUNCAN-McCONNELL, E. HAWORTH, N. WALSH, and S. HASTILOW Continuation of clozapine treatment: practice makes perfect Psychiatr. Bull., June 1, 2003; 27(6): 211 - 213. [Abstract] [Full Text] [PDF] |
||||
| ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| HOME | HELP | FEEDBACK | SUBSCRIPTIONS | ARCHIVE | SEARCH | TABLE OF CONTENTS |
| British Journal of Psychiatry | Advances in Psychiatric Treatment | All RCPsych Journals |